Olympus Corporation has officially launched its next-generation EU-ME3 Ultrasound Processor in the U.S. market, following strong adoption in global regions. This advanced platform combines endoscopic (EUS) and endobronchial (EBUS) ultrasound functionalities into a single, compact system—offering a powerful, all-in-one solution for gastroenterology and pulmonology procedures. The launch aims to support U.S. healthcare providers with enhanced diagnostic capabilities for a broad range of conditions, including cancers of the digestive tract and lungs, where early and accurate detection is crucial for improving patient outcomes.

The EU-ME3 system stands out for its high-resolution imaging and smart technologies like s-FOCUS and Tissue Harmonic Echo, which improve clarity, reduce noise, and minimize artifacts. With backward and forward compatibility with Olympus’ EUS and EBUS endoscopes and miniature probes, the system promotes seamless integration into existing clinical workflows. It also enables tissue stiffness assessments through elastography and shear wave quantification, and offers contrast harmonic echo imaging to enhance lesion characterization. These features collectively empower physicians to conduct both diagnostic and interventional procedures with greater precision, confidence, and efficiency.

As demand for non-invasive diagnostic tools continues to grow amid rising rates of gastrointestinal and pulmonary cancers in the U.S., the EU-ME3 positions Olympus to meet critical healthcare needs while promoting cost-effectiveness for medical facilities. Its modular design and upgradeable features make it a future-ready solution that can evolve with clinical advances and procedural complexity. Olympus’ U.S. launch of the EU-ME3 reinforces its commitment to supporting earlier detection, better staging, and improved treatment planning across two of the most challenging and impactful areas in oncology care.